MicroRNAs in Arterial Hypertension

Current Topics in Medicinal Chemistry

Volumn 13, Issue 13, 2013, Pages 1527-1532

  Synetos, Andreas ^a   Toutouzas, Konstantinos ^a   Stathogiannis, Konstantinos ^a   Latsios, George ^a   Tsiamis, Elefterios ^a   Tousoulis, Dimitris ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Biomarkers; Heart; Hypertension; MicroRNA; Treatment; Vulnerable plaque

Indexed keywords

ANGIOTENSIN; CHEMOKINE RECEPTOR CXCR4; ENDOTHELIN 1; MICRORNA; MICRORNA 100; MICRORNA 125A 5P; MICRORNA 126; MICRORNA 127; MICRORNA 133A; MICRORNA 133B; MICRORNA 146A; MICRORNA 146B 5P; MICRORNA 155; MICRORNA 15A; MICRORNA 17; MICRORNA 191; MICRORNA 208B; MICRORNA 20A; MICRORNA 20B; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 222; MICRORNA 24; MICRORNA 34A; MICRORNA 92A; MICRORNA10A; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; KIDNEY FIBROSIS; MORPHOGENESIS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION;

HUMANS; HYPERTENSION; MICRORNAS;

EID: 84881326741     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990101     Document Type: Article

References (55)

1. The World Health Report 2002-Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization, 2002.
2. Esler, M. D.; Krum, H.; Sobotka, P. A.; Schlaich, M. P.; Schmieder, R. E.; Bohm, M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet, 2010, 376(9756), 1903-1909.
3. Stefanadis, C.; Toutouzas, K.; Synetos, A.; Tsioufis, C.; Karanasos, A.; Agrogiannis, G.; Stefanis, L.; Patsouris, E.; Tousoulis, D. Chemical denervation of the renal artery by vincristine in swine. A new catheter based technique. Int. J. Cardiol., 2012.
4. Krum, H.; Sobotka, P.; Mahfoud, F.; Bohm, M.; Esler, M.; Schlaich, M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation, 2011, 123(2), 209-215.
5. Krum, H.; Schlaich, M.; Whitbourn, R.; Sobotka, P. A.; Sadowski, J.; Bartus, K.; Kapelak, B.; Walton, A.; Sievert, H.; Thambar, S.; Abraham, W. T.; Esler, M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, 2009, 373(9671), 1275-1281.
6. Ambros, V. The functions of animal microRNAs. Nature, 2004, 431(7006), 350-355.
7. Hunter, M. P.; Ismail, N.; Zhang, X.; Aguda, B. D.; Lee, E. J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M. L.; Schmittgen, T. D.; Nana-Sinkam, S. P.; Jarjoura, D.; Marsh, C. B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS. One, 2008, 3(11), e3694.
8. Vickers, K. C.; Palmisano, B. T.; Shoucri, B. M.; Shamburek, R. D.; Remaley, A. T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol., 2011, 13(4), 423-433.
9. Arroyo, J. D.; Chevillet, J. R.; Kroh, E. M.; Ruf, I. K.; Pritchard, C. C.; Gibson, D. F.; Mitchell, P. S.; Bennett, C. F.; Pogosova-Agadjanyan, E. L.; Stirewalt, D. L.; Tait, J. F.; Tewari, M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S A., 2011, 108(12), 5003-5008.
10. Tousoulis, D.; Kampoli, A. M.; Papageorgiou, N.; Androulakis, E.; Antoniades, C.; Toutouzas, K.; Stefanadis, C. Pathophysiology of atherosclerosis: the role of inflammation. Curr. Pharm. Des., 2011, 17(37), 4089-4110.
11. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med., 1999, 340(2), 115-126.
12. Harris, T. A.; Yamakuchi, M.; Ferlito, M.; Mendell, J. T.; Lowenstein, C. J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl Acad. Sci. U. S. A., 2008, 105(5), 1516-1521.
13. Wang, S.; Aurora, A. B.; Johnson, B. A.; Qi, X.; McAnally, J.; Hill, J. A.; Richardson, J. A.; Bassel-Duby, R.; Olson, E. N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell, 2008, 15(2), 261-271.
14. Zernecke, A.; Bidzhekov, K.; Noels, H.; Shagdarsuren, E.; Gan, L.; Denecke, B.; Hristov, M.; Koppel, T.; Jahantigh, M. N.; Lutgens, E.; Wang, S.; Olson, E. N.; Schober, A.; Weber, C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal, 2009, 2(100), ra81.
15. Li, D.; Yang, P.; Xiong, Q.; Song, X.; Yang, X.; Liu, L.; Yuan, W.; Rui, Y. C. MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J. Hypertens., 2010, 28(8), 1646-1654.
16. Sun, H. X.; Zeng, D. Y.; Li, R. T.; Pang, R. P.; Yang, H.; Hu, Y. L.; Zhang, Q.; Jiang, Y.; Huang, L. Y.; Tang, Y. B.; Yan, G. J.; Zhou, J. G. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension, 2012, 60(6), 1407-1414.
17. Martin, M. M.; Lee, E. J.; Buckenberger, J. A.; Schmittgen, T. D.; Elton, T. S. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J. Biol. Chem., 2006, 281(27), 18277-18284.
18. Fang, Y.; Shi, C.; Manduchi, E.; Civelek, M.; Davies, P. F. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(30), 13450-13455.
19. Tousoulis, D.; Briasoulis, A.; Papageorgiou, N.; Tsioufis, C.; Tsiamis, E.; Toutouzas, K.; Stefanadis, C. Oxidative stress and endothelial function: therapeutic interventions. Recent Pat. Cardiovasc. Drug Discov., 2011, 6(2), 103-114.
20. Chen, T.; Huang, Z.; Wang, L.; Wang, Y.; Wu, F.; Meng, S.; Wang, C. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc. Res., 2009, 83(1), 131-139.
21. Toutouzas, K.; Stathogiannis, K.; Synetos, A.; Karanasos, A.; Stefanadis, C. Vulnerable atherosclerotic plaque: from the basic research laboratory to the clinic. Cardiology, 2012, 123(4), 248-253.
22. Cipollone, F.; Felicioni, L.; Sarzani, R.; Ucchino, S.; Spigonardo, F.; Mandolini, C.; Malatesta, S.; Bucci, M.; Mammarella, C.; Santovito, D.; de Lutiis, F.; Marchetti, A.; Mezzetti, A.; Buttitta, F. A unique microRNA signature associated with plaque instability in humans. Stroke, 2011, 42(9), 2556-2563.
23. Raitoharju, E.; Lyytikainen, L. P.; Levula, M.; Oksala, N.; Mennander, A.; Tarkka, M.; Klopp, N.; Illig, T.; Kahonen, M.; Karhunen, P. J.; Laaksonen, R.; Lehtimaki, T. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis, 2011, 219(1), 211-217.
24. Minami, Y.; Satoh, M.; Maesawa, C.; Takahashi, Y.; Tabuchi, T.; Itoh, T.; Nakamura, M. Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur. J. Clin. Invest., 2009, 39(5), 359-367.
25. Papageorgiou, N.; Tousoulis, D.; Androulakis, E.; Siasos, G.; Briasoulis, A.; Vogiatzi, G.; Kampoli, A. M.; Tsiamis, E.; Tentolouris, C.; Stefanadis, C. The role of microRNAs in cardiovascular disease. Curr. Med. Chem., 2012, 19(16), 2605-2610.
26. Gilad, S.; Meiri, E.; Yogev, Y.; Benjamin, S.; Lebanony, D.; Yerushalmi, N.; Benjamin, H.; Kushnir, M.; Cholakh, H.; Melamed, N.; Bentwich, Z.; Hod, M.; Goren, Y.; Chajut, A. Serum microRNAs are promising novel biomarkers. PLoS. One, 2008, 3(9), e3148.
27. Weber, J. A.; Baxter, D. H.; Zhang, S.; Huang, D. Y.; Huang, K. H.; Lee, M. J.; Galas, D. J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem., 2010, 56(11), 1733-1741.
28. Dickinson, B. A.; Semus, H. M.; Montgomery, R. L.; Stack, C.; Latimer, P. A.; Lewton, S. M.; Lynch, J. M.; Hullinger, T. G.; Seto, A. G.; van Rooij, E. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertensioninduced heart failure. Eur. J. Heart Fail., 2013.
29. Li, S.; Zhu, J.; Zhang, W.; Chen, Y.; Zhang, K.; Popescu, L. M.; Ma, X.; Lau, W. B.; Rong, R.; Yu, X.; Wang, B.; Li, Y.; Xiao, C.; Zhang, M.; Wang, S.; Yu, L.; Chen, A. F.; Yang, X.; Cai, J. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation, 2011, 124(2), 175-184.
30. Fichtlscherer, S.; De Rosa, S.; Fox, H.; Schwietz, T.; Fischer, A.; Liebetrau, C.; Weber, M.; Hamm, C. W.; Roxe, T.; Muller-Ardogan, M.; Bonauer, A.; Zeiher, A. M.; Dimmeler, S. Circulating microRNAs in patients with coronary artery disease. Circ. Res., 2010, 107(5), 677-684.
31. Zampetaki, A.; Kiechl, S.; Drozdov, I.; Willeit, P.; Mayr, U.; Prokopi, M.; Mayr, A.; Weger, S.; Oberhollenzer, F.; Bonora, E.; Shah, A.; Willeit, J.; Mayr, M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res., 2010, 107(6), 810-817.
32. Matkovich, S. J.; Wang, W.; Tu, Y.; Eschenbacher, W. H.; Dorn, L. E.; Condorelli, G.; Diwan, A.; Nerbonne, J. M.; Dorn, G. W. 2nd MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ. Res., 2010, 106(1), 166-175.
33. Li, Q.; Song, X. W.; Zou, J.; Wang, G. K.; Kremneva, E.; Li, X. Q.; Zhu, N.; Sun, T.; Lappalainen, P.; Yuan, W. J.; Qin, Y. W.; Jing, Q. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J. Cell Sci., 2010, 123(Pt 14), 2444-2452.
34. Cheng, Y.; Liu, X.; Zhang, S.; Lin, Y.; Yang, J.; Zhang, C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J. Mol. Cell Cardiol., 2009, 47(1), 5-14.
35. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; Castoldi, M.; Soutschek, J.; Koteliansky, V.; Rosenwald, A.; Basson, M. A.; Licht, J. D.; Pena, J. T.; Rouhanifard, S. H.; Muckenthaler, M. U.; Tuschl, T.; Martin, G. R.; Bauersachs, J.; Engelhardt, S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 2008, 456(7224), 980-984.
36. Fernandes, T.; Magalhaes, F. C.; Roque, F. R.; Phillips, M. I.; Oliveira, E. M. Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors: role of microRNAs-16,-21, and-126. Hypertension, 2012, 59(2), 513-520.
37. Boor, P.; Sebekova, K.; Ostendorf, T.; Floege, J. Treatment targets in renal fibrosis. Nephrol. Dial. Transplant., 2007, 22(12), 3391-3407.
38. Liu, Y.; Taylor, N. E.; Lu, L.; Usa, K.; Cowley, A. W. Jr.; Ferreri, N. R.; Yeo, N. C.; Liang, M. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension, 2010, 55(4), 974-982.
39. Wang, B.; Komers, R.; Carew, R.; Winbanks, C. E.; Xu, B.; Herman-Edelstein, M.; Koh, P.; Thomas, M.; Jandeleit-Dahm, K.; Gregorevic, P.; Cooper, M. E.; Kantharidis, P. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol., 2012, 23(2), 252-265.
40. Marques, F. Z.; Campain, A. E.; Tomaszewski, M.; Zukowska-Szczechowska, E.; Yang, Y. H.; Charchar, F. J.; Morris, B. J. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension, 2011, 58(6), 1093-1098.
41. Wang, G.; Kwan, B. C.; Lai, F. M.; Choi, P. C.; Chow, K. M.; Li, P. K.; Szeto, C. C. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am. J. Hypertens., 2010, 23(1), 78-84.
42. Heggermont, W. A.; Heymans, S. MicroRNAs are involved in endorgan damage during hypertension. Hypertension, 2012, 60(5), 1088-1093.
43. Kantharidis, P.; Wang, B.; Carew, R. M.; Lan, H. Y. Diabetes complications: the microRNA perspective. Diabetes, 2011, 60(7), 1832-1837.
44. McArthur, K.; Feng, B.; Wu, Y.; Chen, S.; Chakrabarti, S. MicroRNA-200b regulates vascular endothelial growth factormediated alterations in diabetic retinopathy. Diabetes, 2011, 60(4), 1314-1323.
45. Liu, D. Z.; Tian, Y.; Ander, B. P.; Xu, H.; Stamova, B. S.; Zhan, X.; Turner, R. J.; Jickling, G.; Sharp, F. R. Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J. Cereb. Blood Flow Metab., 2010, 30(1), 92-101.
46. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438(7068), 685-689.
47. Kim, J. H.; Yeom, J. H.; Ko, J. J.; Han, M. S.; Lee, K.; Na, S. Y.; Bae, J. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles. J. Biotechnol., 2011, 155(3), 287-292.
48. Ebert, M. S.; Neilson, J. R.; Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods., 2007, 4(9), 721-726.
49. Bader, A. G.; Brown, D.; Winkler, M. The promise of microRNA replacement therapy. Cancer Res., 2010, 70(18), 7027-7030.
50. Stefanadis, C.; Diamantopoulos, L.; Vlachopoulos, C.; Tsiamis, E.; Dernellis, J.; Toutouzas, K.; Stefanadi, E.; Toutouzas, P. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter. Circulation, 1999, 99(15), 1965-1971.
51. Toutouzas, K.; Karanasos, A.; Riga, M.; Tsiamis, E.; Synetos, A.; Michelongona, A.; Papanikolaou, A.; Triantafyllou, G.; Tsioufis, C.; Stefanadis, C. Optical coherence tomography assessment of the spatial distribution of culprit ruptured plaques and thin-cap fibroatheromas in acute coronary syndrome. EuroIntervention, 2012, 8(4), 477-485.
52. Toutouzas, K.; Grassos, H.; Synetos, A.; Drakopoulou, M.; Tsiamis, E.; Moldovan, C.; Agrogiannis, G.; Patsouris, E.; Siores, E.; Stefanadis, C. A new non-invasive method for detection of local inflammation in atherosclerotic plaques: experimental application of microwave radiometry. Atherosclerosis, 2011, 215(1), 82-89.
53. Toutouzas, K.; Grassos, C.; Drakopoulou, M.; Synetos, A.; Tsiamis, E.; Aggeli, C.; Stathogiannis, K.; Klettas, D.; Kavantzas, N.; Agrogiannis, G.; Patsouris, E.; Klonaris, C.; Liasis, N.; Tousoulis, D.; Siores, E.; Stefanadis, C. First in vivo application of microwave radiometry in human carotids: a new noninvasive method for detection of local inflammatory activation. J. Am. Coll. Cardiol., 2012, 59(18), 1645-1653.
54. Toutouzas, K.; Drakopoulou, M.; Aggeli, C.; Nikolaou, C.; Felekos, I.; Grassos, H.; Synetos, A.; Stathogiannis, K.; Karanasos, A.; Tsiamis, E.; Siores, E.; Stefanadis, C. In vivo measurement of plaque neovascularisation and thermal heterogeneity in intermediate lesions of human carotid arteries. Heart, 2012, 98(23), 1716-1721.
55. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; Li, Q.; Li, X.; Wang, W.; Wang, J.; Jiang, X.; Xiang, Y.; Xu, C.; Zheng, P.; Zhang, J.; Li, R.; Zhang, H.; Shang, X.; Gong, T.; Ning, G.; Zen, K.; Zhang, C. Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res., 2008, 18(10), 997-1006.